Josh Hardman is the founder and editor of Psychedelic Alpha, a newsletter, web resource and boutique consultancy, where he explores the curious intersection of psychedelics and business, sharing regular updates and working with a group of subject-matter experts to maintain numerous free resources and datasets to help individuals and organizations make sense of this burgeoning […]
On Aug. 9, 2023, reMind hosted a webinar with three psychedelic industry experts to discuss strategies and best practices of launching and operating a successful ketamine clinic, including establishing a mission, business plan, client care protocols, fundraising strategies, brand awareness, and location design. The panelists included: Kim Turpin, co-founder of the Pearl Psychedelic Institute; Nykol […]
Katherine MacLean is an accomplished research scientist who has studied the effects of psychedelics on cognitive performance, emotion wellbeing, spirituality, and brain function. As a post doctoral research fellow and faculty member at Johns Hopkins, she worked with Roland Griffiths on the groundbreaking clinical trials of psilocybin that were featured in Michael Pollan’s “How to […]
Derrick Knudsen is a founding partner of Meta Talent Group, a job-placement agency focused on the cannabis and psychedelics industries and strives to be “a bridge for growing companies and purpose-driven leaders who are seeking to improve the world socially and environmentally.” Earlier this year, Knudsen’s firm published its 2023 Psychedelic Salary Guide, which analyzes […]
Dr. Raymond Turpin is the clinical director for The Pearl Psychedelic Institute in Waynesville, North Carolina, and co-principal investigator of The Pearl MDMA Project. He has been studying the therapeutic uses of psychedelics and the relevant literature since the mid-1980s hoping to eventually legally use these medicines in his psychology practice. Dr. Turpin recently shared some […]